Luminex Corporation - A DiaSorin Company

As precision medicine advances, xMAP® Technology is playing a growing role in vaccine development—delivering high-value, cost-effective data from limited samples.

Explore our latest xMAP® Journal Club blog, which highlights how xMAP-based assays are being used in clinical trials to evaluate vaccines across a range of infectious diseases.

Subscribe to the Resource Round-Up to learn more: https://hubs.li/Q04f4fVn0

xMAP® Technology continues to play a pivotal role in modern clinical research, enabling scientists to quantify multiple immune markers from minimal sample volumes—a major advantage in vaccine studies.​

Our latest Journal Club lineup highlights four clinical trials where xMAP-based assays were essential for assessing vaccine safety and immune responses across HIV, HSV-2, HPV, and pneumococcus.​

Read our xMAP® Journal Club blog to discover how multiplexing is driving new understanding in vaccine research.​

https://hubs.li/Q04bpGZZ0​
​